Last updated on July 2017

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis


Brief description of study

This study has a randomized, double-blind, placebo-controlled design to assess the efficacy, pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic dermatitis when applied BID to all atopic dermatitis lesions.

Clinical Study Identifier: NCT03091426

Contact Investigators or Research Sites near you

Start Over

J. (Koos) Burggraaf, MD, PhD

LUMC/Centre for Human Drug Research
Leiden, Netherlands
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.